Compare HLIT & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HLIT | PHAT |
|---|---|---|
| Founded | 1988 | 2018 |
| Country | US | |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 1996 | N/A |
| Metric | HLIT | PHAT |
|---|---|---|
| Price | $10.56 | $11.99 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $13.33 | ★ $17.33 |
| AVG Volume (30 Days) | 769.9K | ★ 828.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.10 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $221.87 |
| Revenue Next Year | $21.77 | $80.37 |
| P/E Ratio | $24.84 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.80 | $2.21 |
| 52 Week High | $11.49 | $18.31 |
| Indicator | HLIT | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 58.49 | 37.06 |
| Support Level | $9.87 | $11.83 |
| Resistance Level | $10.92 | $13.17 |
| Average True Range (ATR) | 0.42 | 0.82 |
| MACD | 0.08 | -0.04 |
| Stochastic Oscillator | 76.79 | 7.78 |
Harmonic Inc engaged in broadband access solutions that enable broadband operators to more efficiently and effectively deploy high-speed internet for data, voice, and video services for their customers and versatile and high-performance video delivery software, products, system solutions and services that enable its customers to efficiently create, prepare, store, playout and deliver a full range of high-quality broadcast and streaming video services to consumer devices, including televisions, personal computers, laptops, tablets, and smartphones. It has two segments, Broadband which provides broadband access solutions and related services, and Others; and Video business provides video processing and production and playout solutions and services, and Others.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.